CSF3 and alcoholic hepatitis: A double‐blind, randomized, placebo‐controlled study to evaluate the safety and efficacy of TAK‐242 (an immunomodulator) alone or in combination with G‐CSF (a stem cell mobilizer) in subjects with severe alcoholic hepatitis and acute‐on‐chronic liver failure. Primary endpoint is safety, with key secondary endpoints including changes in CLIF‐C OF score at Day 14.